Table 2.
Clinical characteristics of organ donors
| Donors n = 35 | |
|---|---|
| Severity scores at admission | |
| APACHE II | 29 (23–33) |
| SOFA | 7 (5–9) |
| Donation type | |
| Brain-death | 19 (54) |
| Maastricht III | 16 (45) |
| Pharmacological treatments during ICU | |
| Systemic corticosteroids | 12 (34) |
| Neuromuscular blockers | 12 (34) |
| Days on neuromuscular blockers | 1 (1–2) |
| Benzodiazepines | 24 (68) |
| Days on benzodiazepines | 1 (0–3) |
| Opioids | 26 (74) |
| Days on opioids | 2 (0–3) |
| Insulin | 12 (34) |
| Subcutaneous | 31 (88) |
| Intravenous | 3 (8) |
| Norepinephrine | 27 (77) |
| Maximal dose, µg/kg/min | 0.3 (0.2–0.6) |
| Dobutamine | 4 (11) |
| Maximum dose, µg/kg/min | 7 (1–16) |
| Enteral nutrition | 18 (51) |
| Days on enteral nutrition | 2 (0–6) |
| Enrolled on a physical therapy program | 4 (11) |
| Complications during ICU stay | |
| Hyperglycemias > 200 mg/dl | 17 (48) |
| Infectious | 12 (34) |
| Non-infectious | 6 (17) |
| Ventilator settings | |
| Controlled modalities | 35 (100) |
| PEEP, cmH2O | 7 (6–8) |
| Analytical variables on day of inclusion | |
| C-reactive protein, mg/dl | 2 (0–17) |
| Troponin, ng/l | 41 (8–485) |
| Creatine kinase, U/L | 179 (54–581) |
| Albumin g/dl | 3 (0.5) |
| ICU evolution data | |
| Days on mechanical ventilation | 5 (2–9) |
| ICU length of stay | 5 (2–9) |
Data expressed as frequencies and percentages [n (%)] or medians and interquartile ranges (IQR or 25th–75th percentile). APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit